Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
Go back to Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer| (AMEX: MKKGY) | Delayed: 32.48 -0.72 (2.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.20 | 52 Week High | $ | |||
| Open | $32.56 | 52 Week Low | $ | |||
| Day High | $32.60 | P/E | N/A | |||
| Day Low | $32.20 | EPS | $ | |||
| Volume | 41,898 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 130.42 -0.5 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.92 | 52 Week High | $65.46 | |||
| Open | $129.93 | 52 Week Low | $47.97 | |||
| Day High | $132.84 | P/E | 88.72 | |||
| Day Low | $129.70 | EPS | $1.47 | |||
| Volume | 6,343,840 | |||||
